NANOG and glioblastoma: However, ALKBH5 has been demonstrated to be an oncogene in glioblastoma through the modification of FOXM1 [30], in breast cancer through m6A demethylation of NANOG [15], and in acute myeloid leukemia via AXL m6A modification [31].